Drug Profile

Parvysmelanotide - Clinuvel Pharmaceuticals

Alternative Names: Parvysmelanotide; VLRX-001

Latest Information Update: 03 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Arizona
Developer Clinuvel Pharmaceuticals
Class Hormonal replacements; Melanocortins; Melanocyte-stimulating hormones; Peptide hormones; Skin disorder therapies
Mechanism of Action Melanocortin type 1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 Sep 2023 Parvysmelanotide is still in preclinical trials for Vitiligo in Singapore (Clinuvel Pharmaceuticals pipeline, September 2023)
28 Sep 2023 No recent reports of development identified for preclinical development in Vitiligo in Singapore (Topical)
12 Nov 2019 Clinuvel Pharmaceuticals files patent applications in various jurisdictions, for VLRX 001

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com